AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00612794
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
Symbicort in Chronic Obstruktive Pulmonary Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2008-02-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18014
- Registration Number
- NCT00612976
Symptoms and Endoscopic Results in Consideration of Pretreatment
Completed
- Conditions
- Gastrointestinal Diseases
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16255
- Registration Number
- NCT00612404
Symbicort in Chronic Obstructive Pulmonary Disease
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2011-01-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64730
- Registration Number
- NCT00611520
Trans GERD: Efficacy and Tolerability of Esomeprazol in Patients Under Ordinary Medical Care Conditions
Completed
- Conditions
- Gastrointestinal Diseases
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2008-02-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 29586
- Registration Number
- NCT00612027
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
Phase 2
Completed
- Conditions
- Ovarian NeoplasmsOvarian Cancer
- Interventions
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 211
- Registration Number
- NCT00610714
- Locations
- 🇬🇧
Research Site, Coventry, United Kingdom
Efficacy of Ciclesonide During the Cold Season in Patients Older Than 12 Years With Persistent Asthma
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2100
- Registration Number
- NCT00608218
- Locations
- 🇩🇪
"Nycomed Deutschland GmbH", Würzburg, Germany
SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
Phase 4
Completed
- Conditions
- Non Small Cell Lung Carcinoma
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 156
- Registration Number
- NCT00608868
- Locations
- 🇰🇷
Research Site, Daegu, Korea, Republic of
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
Completed
- Conditions
- Essential HypertensionLeft Ventricular Hypertrophy
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2008-02-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 686
- Registration Number
- NCT00607633
Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide
Completed
- Conditions
- Essential Hypertension
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2008-02-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1773
- Registration Number
- NCT00608153
© Copyright 2025. All Rights Reserved by MedPath